Janssen Research and Development, Turnhoutseweg 30, 2340 Beerse, Belgium.
Edelris, 60 Avenue Rockefeller, 69008 Lyon, France.
Drug Discov Today. 2021 Oct;26(10):2406-2413. doi: 10.1016/j.drudis.2021.04.019. Epub 2021 Apr 20.
Through the European Lead Factory model, industry-standard high-throughput screening and hit validation are made available to academia, small and medium-sized enterprises, charity organizations, patient foundations, and participating pharmaceutical companies. The compound collection used for screening is built from a unique diversity of sources. It brings together compounds from companies with different therapeutic area heritages and completely new compounds from library synthesis. This generates structural diversity and combines molecules with complementary physicochemical properties. In 2019, the screening library was updated to enable another 5 years of running innovative drug discovery projects. Here, we investigate the physicochemical and diversity properties of the updated compound collection. We show that it is highly diverse, drug-like, and complementary to commercial screening libraries.
通过欧洲先导化合物工厂模式，将工业标准的高通量筛选和命中验证提供给学术界、中小企业、慈善组织、患者基金会和参与的制药公司。用于筛选的化合物库是由独特的多样性来源构建的。它汇集了来自具有不同治疗领域背景的公司的化合物和完全来自文库合成的全新化合物。这产生了结构多样性，并将具有互补理化性质的分子结合在一起。2019 年，筛选库进行了更新，以支持另外 5 年的创新药物发现项目。在这里，我们研究了更新后的化合物库的理化性质和多样性特征。我们表明，它具有高度的多样性、类药性和与商业筛选库的互补性。
